|
COMPUGEN LTD, (CGEN) Stock Rating Learn More
| Our Overall Rating on COMPUGEN LTD, CGEN is Not Available | | Compugen, Ltd. develops platforms, discovery engines, and related technologies that enable the discovery and analysis of genes and gene-based products, as well as mRNAs and proteins. Its platforms comprise LEADS computational biology platform, which analyzes genomic and expressed sequence data to enable discovery of genes, mRNAs, and proteins; and discovery engines that enable its researchers to identify proteins and mRNAs with predetermined properties for therapeutic and diagnostic development. The company initiates the predictive modeling of alternative splicing, antisense, and the RNA editing that provides the basis for understandings of additional biological phenomena. Compugen has an early stage in-house pipeline consisting of selected therapeutic protein candidates discovered by the company; and additional discoveries that are out-licensed for development. It also focuses on novel splice variants of known and validated therapeutic proteins, as well as novel diagnostic markers. These novel proteins constitute an intellectual property portfolio, which includes novel prostate specific antigens, a novel vascular endothelial growth factor, a splice variant of CD40, and other proteins. The company operates primarily in the United States, Israel, Europe, and the Far East. Compugen has a collaboration agreement with Ortho-Clinical Diagnostics, Inc. for the development and commercialization of immunoassay diagnostic markers. The company was established in 1993 and is headquartered in Tel Aviv, Israel. | | Our Not Available Rating on CGEN was issued on 11/20/2008 |
COMPUGEN LTD Technical Rating
|
